Meadow Creek Investment Management’s Acceleron Pharma XLRN Stock Holding History

Meadow Creek Investment Management’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$36K	Sell	924 -140	-13%	-$6.07K	﹤0.01%	1283
2019 Q2	$44K	Sell	1,064 -7,924	-88%	-$328K	﹤0.01%	1288
2019 Q1	$419K	Sell	8,988 -56	-0.6%	-$2.46K	0.01%	755
2018 Q4	$394K	Sell	9,044 -6,692	-43%	-$334K	0.01%	729
2018 Q3	$901K	Sell	15,736 -308	-2%	-$15.1K	0.02%	487
2018 Q2	$779K	Buy	16,044 +1,764	+12%	+$64.3K	0.02%	500
2018 Q1	$558K	Buy	+14,280	New	+$607K	0.01%	611

Other funds holding XLRN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Meadow Creek Investment Management's XLRN Position: Q3 2019 in Review

Meadow Creek Investment Management reduced its Acceleron Pharma (XLRN) stake by 13% in Q3 2019, selling an estimated $6.07K and leaving 924 shares worth $36K. The position accounts for ﹤0.01% of the portfolio, ranked #1283.

Meadow Creek Investment Management first reported a position in XLRN in Q1 2018 and has held it in 7 quarters since. The position peaked at $901K in Q3 2018. 172 funds tracked by Wall St. Rank hold XLRN as of Q3 2019.

Meadow Creek Investment Management held 924 shares of Acceleron Pharma worth $36K as of Q3 2019.
Meadow Creek Investment Management sold 140 Acceleron Pharma shares in Q3 2019, an estimated $6.07K.
Acceleron Pharma made up ﹤0.01% of Meadow Creek Investment Management's portfolio in Q3 2019, its #1283 holding.
Meadow Creek Investment Management first reported a position in Acceleron Pharma in Q1 2018 and has held it in 7 quarters since.
Meadow Creek Investment Management's Acceleron Pharma position peaked at $901K in Q3 2018.
172 funds tracked by Wall St. Rank held Acceleron Pharma as of Q3 2019.

Based on Meadow Creek Investment Management's 13F filing for Q3 2019, filed 14 Nov 2019.